Bortezomib-Induced Blepharitis: A Case Report_Crimson Publishers

Bortezomib-Induced Blepharitis: A Case Report  by Kamal AlZahran in Crimson Publishers: Open access journal of surgery impact factor

Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma and has known manageable toxicities. Blepharitis is an inflammatory condition of the eyelid that leads to formation of chalazia both causing visual field disturbance. Bortezomib induced blepharitis has not been well reported in the literature. we present a case of 76-year-old lady with multiple myeloma who developed bortezomibinduced blepharitis and chalazia. Patient was successfully treated after topical ocular therapy, systemic antibiotherapy and omission of bortezomib. Multiple myeloma is characterized by a neoplastic proliferation of plasma cells in the bone marrow producing a monoclonal immunoglobulin and resulting in extensive skeletal destruction. One of the used treatment regimens for MM being the VCD protocol (Velcade® or Bortezomib, Cyclophosphamide and Dexamethasone) [1,2]. Bortezomib is a proteasome inhibitor that acts by disrupting the cell cycle and inducing apoptosis, usually tolerated in the outpatient settings with manageable toxicities, the most common ones being peripheral neuropathy and thrombocytopenia [1,2]. Blepharitis is an inflammatory condition of the eyelid margin causing ocular and visual discomfort leading to formation of chalazia (lipogranulomatous lesions) [3,4].

https://crimsonpublishers.com/smoaj/fulltext/SMOAJ.000561.php

For more articles on crimson publishers

Please click on link:  https://crimsonpublishers.com/

For more articles on Surgical Medicine Open Access Journal
Please click on link: https://crimsonpublishers.com/smoaj/index.php

Blogger
Follow On Publons  : https://publons.com/publisher/6342/crimson-publishers

Follow On Linkedin : https://www.linkedin.com/company/crimsonpublishers